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Summary: Mixed outcome endpoints that combine multiple continuous and discrete components to form co-primary,
multiple primary or composite endpoints are often employed as primary outcome measures in clinical trials. There
are many advantages to joint modelling the individual outcomes using a latent variable framework, however in order
to make use of the model in practice we require techniques for sample size estimation. In this paper we show how the
latent variable model can be applied to the three types of joint endpoints and propose appropriate hypotheses, power
and sample size estimation methods for each. We illustrate the techniques using a numerical example based on the
four dimensional endpoint in the MUSE trial and find that the sample size required for the co-primary endpoint is
larger than that required for the individual endpoint with the smallest effect size. Conversely, the sample size required
for the multiple primary endpoint is reduced from that required for the individual outcome with the largest effect
size. We show that the analytical technique agrees with the empirical power from simulation studies. We further
illustrate the reduction in required sample size that may be achieved in trials of mixed outcome composite endpoints
through a simulation study and find that the sample size primarily depends on the components driving response and
the correlation structure and much less so on the treatment effect structure in the individual endpoints.
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11. Introduction
Sample size estimation plays an integral role in the design of a study. The objective is to
determine the minimum sample size that is large enough to detect, with a specified power, a
clinically meaningful treatment effect. Although it is crucial that investigators have enough
patients enrolled to detect this effect, overestimating the sample size also has ethical and
practical implications. Namely, in a placebo-controlled trial, more patients are subjected to
a placebo arm than is necessary, therefore withholding access to potentially beneficial drugs
from them and delaying access to future patients. Furthermore it results in longer, more
expensive trials, using resources that could be allocated elsewhere.
One vital aspect of sample size determination is the primary endpoint. Usually this is a single
outcome, however in some instances there may be multiple outcomes of equal relevance. Var-
ious combinations of multiple outcomes may be selected as the primary endpoint, depending
on the hypothesis of interest. One option is a co-primary endpoint, which requires that a
treatment effect must occur in all of the selected primary outcomes in order for the treatment
to be classed as effective overall. Alternatively, multiple primary endpoints may be of interest
and thus overall effectiveness may be concluded if a treatment effect occurs in at least one
of the outcomes. Another possibility is a composite endpoint, involving some combination of
the outcomes which reduces to a one dimensional outcome used for inference. In composite
responder endpoints, the outcomes are combined by labelling patients as ‘responders’ or ‘non-
responders’ based on whether they exceeded predefined thresholds in each of the outcomes,
collapsing the information contained in the components into an overall binary, ordinal or
categorical response indicator.
For each of these endpoints, the individual outcomes may be a mix of multiple continuous,
ordinal and binary measures. In this case, there is a lack of an obvious multivariate distribu-
tion for the joint outcomes. One possible way to jointly model the outcomes is using a latent
variable framework arising in the graphical modelling literature, which assumes that the dis-
crete outcomes are latent continuous variables subject to estimable thresholds, and proceed
with a multivariate normal distribution (Ashford and Sowden, 1970; Chib and Greenberg,
1998). By employing this framework we can take account of the correlation between the
outcomes, improve the handling of missing data in individual components and potentially
increase efficiency. Furthermore, in the case of multiple primary outcomes, it may reduce the
severity of multiple testing corrections required.
A key barrier of benefiting from these advantages is the lack of techniques for sample
size determination. If a mixed outcome composite is selected as the primary endpoint in
a trial then the sample size calculation is typically based on the overall binary responder
endpoint, analysed using a standard binary method such as logistic regression. Sample size
calculations performed in this way are valid but when applying the latent variable model in
this context it is desirable to avail of the greatly increased power, hence requiring a technique
based on the novel joint modelling approach (McMenamin et al., 2019). In the case of co-
primary and multiple primary endpoints, the trials are typically powered for the continuous
component, see for example (Breedveld et al., 2006). The co-primary and multiple primary
outcomes proposed may also be restricted to being on the same scale. In this case standard
multivariate distributions can be used for which some methods have been proposed, however
these methods are not routinely implemented.
A recent and comprehensive overview of the existing literature for sample size determination
in clinical trials with multiple endpoints is provided by Sozu et al. (2015). The review found
many proposals for power and sample size calculations for multiple continuous outcomes.
Some of these suggestions were based on assuming that the endpoints were bivariate normally
distributed (Sozu et al. (2012); Xiong et al. (2005)) and extended for the case of more than
two endpoints (Sozu et al. (2011); Sugimoto et al. (2012)). Other work focused on testing
3procedures and found two-sample t-tests, which reject only if each t-statistic is significant,
to be conservative and biased (Eaton and Muirhead (2007); Julious and McIntyre (2012)).
Other efforts were focused on investigating and controlling the type I error rate (Senn (2003);
Chuang-Stein et al. (2007); Kordzakhia et al. (2010); Hung and Wang (2009)). All of these
methods focus on the requirement of effects on all endpoints. Methods for effects on at
least one endpoint also exist (Senn (2003); Hung and Wang (2009); Dmitrienko et al. (2010);
Gong et al. (2000)).
Less comprehensive consideration has been given to the case of multiple binary endpoints.
Five methods of power and sample size calculation based on three association measures are
introduced for co-primary binary endpoints by Sozu et al. (2010). Sample size calculation for
trials using multiple risk ratios and odds ratios for treatment effect estimation is discussed by
Hamasaki et al. (2012). Song (2009) explores co-primary endpoints in non-inferiority clinical
trials. Consideration has also been given to the case where two co-primary endpoints are both
time-to-event measures where effects are required in both endpoints (Hamasaki et al. (2013);
Sugimoto et al. (2011, 2013)) and at least one of the endpoints (Sugimoto et al. (2012)).
Even less consideration has been given to the mixed outcome setting. One paper considers
overall power functions and sample size determinations for multiple co-primary endpoints
that consist of mixed continuous and binary variables (Sozu et al. (2012)). They assume that
response variables follow a multivariate normal distribution, where binary variables are ob-
served in a dichotomized normal distribution, and use Pearson’s correlations for association.
A modification was suggested to this method by Wu and de Leon (2013) which involved using
latent-level tests and pairwise correlations and provided increased power. These methods
focus on the co-primary endpoint case, where effects are required in all outcomes. The case
of multiple primary or composite responder endpoints where the components are measured
on different scales has not been considered, each of which will require distinct hypotheses.
In this paper we will build on the work by Sozu et al. (2012) and Wu and de Leon (2013)
for co-primary continuous and binary endpoints to include any combination of continuous,
ordinal and binary outcomes for co-primary, multiple primary and composite endpoints. The
paper will proceed as follows. We will introduce the latent variable model and detail how it
can be used in each context. We will illustrate the appropriate hypothesis tests for each of
the three combinations of mixed outcomes and propose power calculation and sample size
estimation techniques. We illustrate the methods on a four dimensional endpoint consisting
of two continuous, one ordinal and one binary outcome using a numerical example based on
the MUSE trial (Furie et al., 2017). We further investigate empirically the behaviour of the
power and sample size when employing this approach for a composite outcome and compare
it with the standard binary method for a range of scenarios and data structures. Finally we
conclude with a discussion and recommendations for practice.
2. Latent Variable Model
We begin by constructing the model in McMenamin et al. (2019). Let nT and nC represent
the number of patients in the treatment group and the control group respectively and let K be
the number of outcomes measured for each patient. Let YTi = (YT i1, ..., YT iK)
T , i = 1, ..., nT
be vector of K responses for patient i on the treatment arm and YCi = (YCi1, ..., YCiK)
T , i =
1, ..., nC the vector of K responses for patient i on the control arm. Without loss of generality,
the first 1 6 k 6 km elements of YTi and YCi are observed as continuous variables, the next
km < k 6 ko are observed as ordinal and the remaining ko < k 6 K are observed as binary.
We use the biserial model of association by Tate (1955), which is based on latent continuous
measures manifesting as discrete variables. Formally, we say that YTi and YCi have latent
variables Y∗
Ti
and Y∗
Ci
respectively, where Y∗
Ti
∼ NK(µT ,ΣT ) and Y∗Ci ∼ NK(µC ,ΣC)
5ΣT =

σ2T1 . . . ρT1KσT1σTK
...
. . .
...
ρT1KσT1σTK · · · σ2TK
 , ΣC =

σ2C1 . . . ρC1KσC1σCK
...
. . .
...
ρC1KσC1σCK · · · σ2CK

For k 6= k′ : 1 6 k < k′ 6 K let V ar(YT ik) = σ2Tk, V ar(YCik) = σ2Ck, Corr(YT ik, YT ik′) =
ρTkk′, Corr(YCik, YCik′) = ρCkk′, where ρTkk′ and ρCkk′ are the association measures between
the endpoints. Then, for:
• 1 6 k 6 km : YT ik = Y ∗T ik and YCik = Y ∗Cik
• km < k 6 ko :
YT ik =

0 if τk0 6 Y
∗
T ik < τk1,
1 if τk1 6 Y
∗
T ik < τk2,
...
...
wk if τkwk 6 Y
∗
T ik < τk(wk+1)
YCik =

0 if τk0 6 Y
∗
Cik < τk1,
1 if τk1 6 Y
∗
Cik < τk2,
...
...
wk if τkwk 6 Y
∗
Cik < τk(wk+1)
• ko < k 6 K : YT ik =

0 if τk0 6 Y
∗
T ik < τk1,
1 if τk1 6 Y
∗
T ik < τk2
YCik =

0 if τk0 6 Y
∗
Cik < τk1,
1 if τk1 6 Y
∗
Cik < τk2
We set τk0 = −∞, τk(wk+1) =∞ and the intercepts equal to zero for km < k 6 ko in order
to estimate the cut-points. Additionally, τk0 = −∞, τk1 = 0, τk2 =∞ for ko < k 6 K so that
the intercepts can be estimated for the outcomes observed as binary. Furthermore, for km <
k 6 K, σ2Tk = σ
2
Ck = 1. We assume that Σ = ΣT = ΣC and partition Σ =
 Σ11 Σ12
Σ21 Σ22
 so
that Σ is as shown in (1).
Σ =

σ21 · · · ρ1kmσ1σkm ρ1km+1σ1 · · · ρ1Kσ1
...
. . .
...
...
. . .
...
ρ1kmσ1σkm · · · σ2km ρkmkm+1σkm · · · ρkmKσkm
ρ1km+1σ1 . . . ρkmkm+1σkm 1 . . . ρkm+1K
...
. . .
...
...
. . .
...
ρ1Kσ1 · · · ρkmKσkm ρkm+1K · · · 1

(1)
For km < k 6 K we can define the conditional mean for outcome k as µk|1...km = µ
∗
k +
Σ12Σ
−1
22 (yk − µk) where µ∗k is the latent mean. The correlation matrix for the outcomes can
then be defined using the pairwise correlations between elements of Yi and Y
∗
i as below.
Γ =
D− 12Σ11D− 12 D− 12Σ12
Σ22
 (2)
where D−
1
2 = diag(σ−11 , ..., σ
−1
km
).
This framework can be used as the basis for which to jointly model multiple continuous,
ordinal and binary outcomes. However, the endpoints of interest may differ, with distinct
hypotheses for each, thus requiring different techniques for estimating the sample size. We
present approaches for sample size determination in the case of mixed co-primary endpoints,
multiple primary endpoints and composite endpoints below, highlighting the different as-
sumptions and requirements in each case.
3. Sample Size Estimation
3.1 Co-primary Endpoints
One potential application of the latent variable model is to mixed outcome co-primary
endpoints. In this case, a treatment must be shown to be effective as measured by each
7of the outcomes in order to be deemed effective overall. Sozu et al. (2012) propose a method
to calculate the sample size for a mixture of continuous and binary endpoints using this
framework, which was amended by Wu and de Leon (2013) to use latent level tests for
increased power. We generalise this work to include ordinal outcomes, as shown below.
3.1.1 Hypothesis Testing. In many clinical trials the hypothesis of interest is based on
superiority, namely that the proposed treatment will perform better than the control treat-
ment, specified by some predefined margin. The null hypothesis is that the difference in
treatment effects for the treatment arm and control arm is zero. This is straightforward
to formalise in the case of one endpoint but less so when there are multiple co-primary
endpoints, particularly when they are measured on different scales. The hypothesis of interest
is as shown in (3).
H0 : ∃k s.t. piTk − piCk 6 0
H1 : piTk − piCk > 0 ∀k
(3)
For ko < k 6 K we can specify piT ik = P (YT ik = 0) = P (Y
∗
T ik < 0) and piCik = P (YCik =
0) = P (Y ∗Cik < 0) for the treatment and control group respectively. We can generalise this
assumption to account for the ordinal endpoints based on the fact that for km < k 6 ko
piT ik = P (YT ik = wk) = P (τkwk < Y
∗
T ik < τk(wk+1)). Therefore, multiple levels in the ordinal
outcomes can be considered by selecting the appropriate τ thresholds. For instance, piT ik =
P (YT ik = 0) + P (YT ik = 1) + P (YT ik = 2) = P (−∞ < Y ∗T ik < τk3). As the latent means are
estimable by maximum likelihood, µT i1 = Φ
−1(piT i1), . . . , µ
∗
T iK = Φ
−1(piT iK) in the treatment
group and µCi1 = Φ
−1(piCi1), . . . , µ
∗
CiK = Φ
−1(piCiK) in the control group.
We can proceed by specifying that the hypothesis in (3) holds if and only if the hypothesis
H∗0 : ∃k s.t. δ∗k 6 0
H∗1 : δ
∗
k > 0 ∀k
(4)
holds, where δ∗k = µ
∗
Tk − µ∗Ck, as highlighted by Wu and de Leon (2013). The maximum
likelihood estimates µˆ∗Tk and µˆ
∗
Ck can be used for a test of H
∗
0 and the variance of this test
statistic can be obtained using the inverse of the Fisher information matrix.
3.1.2 Overall Power. Having specified the hypothesis to include ordinal outcomes, the
power in this case is as defined for mixed continuous and binary co-primary endpoints
(Wu and de Leon, 2013), as shown in (5).
1− β = P
 km⋂
k=1
{Zk > zα}
K⋂
km+1
{Z∗k > zα} | δ
 ≃ P ( K⋂
k=1
{Z†k > z†k} | δ
)
(5)
for δ = (δ1, ..., δkm , ..., δko, ..., δK)
T 6= 0 and
Z†k =

Zk − δk
σk
√
κnT
1 + κ
=
Y¯Tk − Y¯Ck − δk
σk
√
1 + κ
κnT
, k = 1, ..., km
Z∗k − δ∗k
√
κnT
1 + κ
=
µˆ∗Tk − µˆ∗Ck − δ∗k√
1 + κ
κnT
, k = km+1, ..., K
(6)
z†k =

zα − δk
σk
√
κnT
1 + κ
, k = 1, ..., km
zα − δ∗k
√
κnT
1 + κ
, k = km+1, ..., K
(7)
where δk = µTk − µCk, δ∗k = µ∗Tk − µ∗Ck, κ = nC/nT and zα is the (1 − α)100th standard
normal percentile. Therefore, the power can be approximated as shown in (8).
1− β ≃ P
(
K⋂
k=1
{Z†k > z†α} | δ
)
= ΦK
(
−z†1, ...,−z†K ; Γ
)
(8)
3.1.3 Sample Size Calculation. Assuming nT = nC = n it is possible, as discussed by
Sozu et al. (2015), to rearrange (8) to obtain a sample size formula in terms of n as shown
9in (9),
n =
(Ck + z1−α)
2
kδ2k
(9)
where Ck is the solution of
1− β =
∫ γ1Ck+z1−α(γ1−1)
−∞
. . .
∫ γk−1Ck+z1−α(γk−1−1)
−∞
∫ Ck
−∞
f (z1, . . . , z
∗
K ; 0,Γ) dz
∗
K . . . dz1 (10)
3.2 Multiple Primary Endpoints
Multiple primary endpoints are distinct from co-primary endpoints in that the treatment
needs to be shown to work in at least one of the outcomes in order to be classed as effective
overall. We would expect the sample size required to be reduced compared with the co-
primary endpoint case which would require power to detect treatments in all outcomes. We
can extend the work of Sozu et al. (2012) and Wu and de Leon (2013) to allow for sample
size estimation for multiple primary endpoints.
3.2.1 Hypothesis Testing. The hypothesis of interest, accounting for the fact that a sig-
nificant effect in only one outcome is required, is shown below.
H0 : piTk − piCk 6 0 ∀k
H1 : ∃k s.t. piTk − piCk > 0
(11)
As before, piTk and piCk can be determined for km < k 6 ko using the relevant τ thresholds.
H∗0 : δ
∗
k 6 0 ∀k
H∗1 : ∃k s.t. δ∗k > 0
(12)
The difference in latent means δ∗k = µ
∗
Tk − µ∗Ck and their variance are estimated using the
maximum likelihood estimates and Fisher information matrix respectively, as before.
3.2.2 Overall Power. The overall power can then be specified as shown below
1− β = P
 km⋃
k=1
{Zk > zα}
K⋃
km+1
{Z∗k > zα} | δ
 ≃ P ( K⋃
k=1
{Z†k > z†k} | δ
)
(13)
where Z†k and z
†
k is as defined for co-primary endpoints and nT = nC = n. In order to obtain
an appropriate power function we rely on the inclusion-exclusion principle.
P
(
K⋃
k=1
{Z†k > z†k} | δ
)
=
K∑
k=1
P
(
{Z†k > z†k} | δ
)
−
∑
k<l
P
(
{Z†k > z†k} ∩ {Z†l > z†l } | δ
)
+
∑
k<l<m
P
(
{Z†k > z†k} ∩ {Z†l > z†l } ∩ {Z†m > z†m} | δ
)
+ . . .+ (−1)K−1
∑
k<...<K
P
(
K⋂
k=1
{Z†k > z†k} | δ
)
A closed form expression for the overall power is shown in (14).
P
(
K⋃
k=1
{Z†k > z†k} | δ
)
=
K∑
i=1
(−1)i−1 ∑
I⊆{1,...,K}
P
(⋂
k∈I
{Z†k > z†k} | δ
) (14)
Assuming nT = nC = n, we can input different values for n to achieve the required power.
3.3 Composite Endpoints
A review conducted by Wason et al. (2019) showed that composite responder endpoints are
widely used. They identified many clinical areas in which they are common, such as oncology,
rheumatology, cardiovascular and circulation. As shown by McMenamin et al. (2019), the
latent variable framework may be used to model the underlying structure of these mixed
outcome composite endpoints to greatly improve efficiency. The joint distribution of the
continuous, ordinal and binary outcomes is modelled using the latent variable structure as
before. However, in this case the endpoint of interest is a composite responder endpoint and
so the required quantity is some function of the probability of response in the treatment
group pT and in the control group pC .
For instance, an overall responder index Si can be formed for patient i, where Si = 1 if
Yi1 6 η1, . . . , Y
∗
iK 6 ηK and 0 otherwise, where the quantities (η1, . . . , ηK) are predefined
responder thresholds. Generalisations where response just requires a certain number of the
components to meet the thresholds are possible, but involve more complex sums. We can
specify piT and piC , the probability of response for patient i in the treatment arm and control
11
arm respectively, as shown in (15),
piT = P (Si = 1|Ti = 1) =
∫ η1
−∞
. . .
∫ ηK
−∞
fY1,...,YK(yi1, . . . , yiK |Ti = 1, θ)dyK . . . dy1
piC = P (Si = 1|Ti = 0) =
∫ η1
−∞
. . .
∫ ηK
−∞
fY1,...,YK(yi1, . . . , yiK |Ti = 0, θ)dyK . . . dy1
(15)
where θ is the vector of model parameters and we assume that pT ∼ N(δT , σδT ) and pC ∼
N(δC , σδC ). As in the case of co-primary and multiple primary endpoints, the assumptions
allow us to estimate latent means (µ∗km+1, . . . , µ
∗
K) for the observed discrete components using
the model parameters.
3.3.1 Hypothesis Testing. In the mixed outcome composite endpoint setting, note that
although we are exploiting the latent multivariate Gaussian structure for efficiency gains
we are ultimately still interested in a one dimensional endpoint, such as the difference in
response probabilities between the treatment and control arms of the trial. This is distinct
from the co-primary and multiple primary endpoints cases, where the overall hypothesis test
must be based on some union or intersection of the hypotheses for the individual outcomes.
For the composite endpoint we can formulate the hypothesis as shown in (16),
H0 : pT − pC 6 0
H1 : pT − pC > 0
(16)
where pT and pC are as in (15). For sample size estimation, we require the distribution of δ
under H1, which we can assume to be δ ∼ N(δT − δC , σ2δ ). The hypothesis can therefore be
stated as
H0 : δ
∗
6 0
H1 : δ
∗ > 0
(17)
where δ∗ = δ∗T − δ∗C , δ∗T = ΦK(η1, · · · , ηK ;µ∗T ,ΣT ), δ∗C = ΦK(η1, · · · , ηK ;µ∗C ,ΣC) and
ΦK(.;µ,Σ) is the K-dimensional multivariate normal distribution function, with mean vector
µ and covariance matrix Σ. Estimates of the quantities can be obtained using the maximum
likelihood estimates for the model parameters, as in the co-primary and multiple primary
endpoint settings, so that δˆ∗T = ΦK(η1, · · · , ηK ; µˆ∗T , Σ̂T ) and δˆ∗C = ΦK(η1, · · · , ηK ; µˆ∗C , Σ̂C),
where µT
∗ is the K-dimensional vector of mean values in the treatment arm and µC
∗ is the
corresponding vector for the control arm. Using a Taylor series expansion, we can obtain the
quantity σ2δ as follows.
var(δˆ∗) ≈ (′′δ)TCov(θˆ)(′′δ) (18)
Then, v̂ar(δˆ∗) = (′′δT )
T Ĉov(θˆ)(′′δT ), where
′′δ is the vector of partial derivatives of δ∗ with
respect to each of the parameter estimates. One potential difficulty for conducting sample size
estimation using the latent variable model in practice is that the vector of model parameters
θ may be large depending on the number of outcomes. We can obtain θˆ and covariance
matrix Ĉov(θˆ) by fitting the model to pilot trial data. If all model parameters and their
covariance matrix could be specified fitting the model on pilot data would not be required,
however this would be difficult in practice, especially for more than two components.
3.3.2 Overall Power. To test the hypothesis in (16), we need to determine the critical
value, cv. As the endpoint of interest is specified in terms of the overall one dimensional
composite endpoint, we can use the formula assumed when employing the standard test
of proportions technique and the approximation for the distribution of the test statistic δ
under H1 so that cv = σδzα. As σδ =
√
σδT
nT
+
σδC
nC
, we can assume that σT = σC = σ and
nT = nC = n, so that δ ∼ N(δT − δC , 2σ2/n). The power is deduced in the standard way, as
demonstrated below.
1− β = P
(
p¯T − p¯C > zα
√
2σ2/n | H1
)
= P
(
Z >
zα
√
2σ2/n− δ∗√
2σ2/n
| H1
)
= Φ
(
δ∗√
2σ2/n
− zα
)
(19)
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3.3.3 Sample Size Calculation. Note that σ2δ estimated using (18) gives
2σ2
n
, however to
obtain a formula in terms of the required sample size we will need to separate n from the
variance estimate. By fitting the model to pilot trial data we can obtain an estimate for σ2,
as the value of n will be known in this instance and n can be obtained using (20).
n =
2σ2(z1−β + zα)
2
δ∗2
(20)
This is similar to the sample size equation used for the binary method, however σ will be
different and δ∗ is obtained using latent means as opposed to provided directly.
4. Numerical Application
4.1 MUSE trial
We illustrate the technique for sample size determination using the MUSE trial (Furie et al.,
2017). The trial was a phase IIb, randomised, double-blind, placebo-controlled study inves-
tigating the efficacy and safety of anifrolumab in adults with moderate to severe systemic
lupus erythematosus (SLE). Patients (n=305) were randomised (1:1:1) to receive anifrol-
umab (300mg or 1000mg) or placebo, in addition to standard therapy every 4 weeks for 48
weeks. The primary endpoint in the study was the percentage of patients achieving an SLE
Responder Index (SRI) response at week 24, with sustained reduction of oral corticosteroids
(<10mg/day and less than or equal to the dose at week 1 from week 12 through 24). SRI
is comprised of a continuous Physician’s Global Assessment (PGA) measure, a continuous
SLE Disease Activity Index (SLEDAI) measure and an ordinal British Isles Lupus Assesment
Group (BILAG) measure (Luijten et al., 2012). The study had a target sample size of 100
patients per group based on providing 88% power at the 0.10 alpha level, to detect at least
20% absolute improvement in SRI(4) response rate at week 24 for anifrolumab relative to
placebo. The investigators assumed a 40% placebo response rate.
4.2 Model
In this case (Y1, Y2, Y3, Y4) are the two continuous, ordinal and binary components respec-
tively and (Y1, Y2, Y
∗
3 , Y
∗
4 ) ∼ N4 (µ∗,Σ) where,
µ∗ = (µ1, µ2, µ
∗
3, µ
∗
4)
T Σ =

σ21 ρ12σ1σ2 ρ13σ1 ρ14σ1
ρ12σ1σ2 σ
2
2 ρ23σ2 ρ24σ2
ρ13σ1 ρ23σ2 1 ρ34
ρ14σ1 ρ24σ2 ρ34 1

(21)
and the ordinal and binary components may be related to their latent variables as shown in
(22). The thresholds (τ31, τ32, τ33, τ34) are estimated from the data.
Yi3 =

0 if −∞ < Y ∗i3 < τ31,
1 if τ31 6 Y
∗
i3 < τ32,
2 if τ32 6 Y
∗
i3 < τ33,
3 if τ33 6 Y
∗
i3 < τ34,
4 if τ34 6 Y
∗
i3 <∞,
Yi4 =

0 if −∞ < Y ∗i4 < 0,
1 if 0 6 Y ∗i4 <∞
(22)
We can use the MUSE trial to design future studies where we assume that the endpoints
of interest are co-primary, multiple primary and composite endpoints. The overall power
functions for each are shown below.
Powerco = Φ4
(
−z†1,−z†2,−z†3,−z†4; Σ
)
Powermult =
4∑
i=1
(−1)i−1 ∑
I⊆{1,2,3,4}
Φk∈I
(
−z†k; Σ
)
Powercomp = Φ(−z)
where z†k = zα − δk√
2σ
2
k
/n
for k = {1, 2} and z†k = zα − δ
∗
k√
2/n
for k = {3, 4}. In the composite
setting z = δ
∗√
2σ
2/n
− zα where σ is estimated using (18).
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4.3 Results
The power functions for all three joint endpoints are shown, along with that of the individual
endpoints, in Figure 1. The multiple primary endpoints have the highest power, where 80%
is achieved for n = 29. This is followed closely by the composite endpoint, which requires
n = 37. Note that the power function for the composite endpoint is almost identical to
that of PGA, the component with the highest effect size. As we would expect the power is
considerably lower for co-primary endpoints, which would require n = 400 for 80% power.
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Figure 1: Power function for individual SLEDAI (continuous), PGA (continuous), BILAG
(ordinal) and Taper (binary) outcomes and the power functions with when they are treated
as co-primary, multiple primary and composite endpoints using data from the MUSE trial
Table 1 shows the sample sizes required in each group, for the co-primary and multiple
primary endpoints to obtain an overall power of at least 80% to detect a difference of 0.88
in SLEDAI, 0.38 in PGA, 0.24 in BILAG and 0.40 in the taper outcome at alpha level
α = 0.025, based on the values observed in the trial. We also allow for uncertainty in the
variance of the continuous measures by setting σ21 = 18, 19, 20 and σ
2
2 = 0.35, 0.45, 0.55, 0.65.
The sample sizes required for each individual endpoint are also shown based on achieving a
power of at least 80%. Allowing for uncertainty in the variance of the SLEDAI outcome varies
the required sample size for the co-primary endpoint but not the multiple primary endpoint.
Table 1: Sample sizes n = nC = nT for the co-primary and multiple primary endpoints for
overall power 1 − β ≈ 0.80, α = 0.025, k2 = 2, ko = K = 1 using the MUSE trial data.
SS1, SS2, SS3, SS4 are sample sizes required per group for the individual endpoints for a
power of at least 1− β = 0.80
SLEDAI PGA BILAG Taper nco nmult SS1 SS2 SS3 SS4
δ1 σ
2
1 δ2 σ
2
2 (piT3, piC3) δ
∗
3 (piT4, piC4) δ
∗
4
0.88 18 0.38 0.35 (0.97,0.95) 0.24 (0.54,0.38) 0.40 403 29 365 39 273 99
0.88 19 0.38 0.35 (0.97,0.95) 0.24 (0.54,0.38) 0.40 419 29 386 39 273 99
0.88 20 0.38 0.35 (0.97,0.95) 0.24 (0.54,0.38) 0.40 435 29 406 39 273 99
0.88 18 0.38 0.45 (0.97,0.95) 0.24 (0.54,0.38) 0.40 403 34 365 49 273 99
0.88 18 0.38 0.55 (0.97,0.95) 0.24 (0.54,0.38) 0.40 403 39 365 60 273 99
0.88 18 0.38 0.65 (0.97,0.95) 0.24 (0.54,0.38) 0.40 403 42 365 71 273 99
The opposite is true when the assumed variance of the PGA outcome is changed, namely
affecting the sample size required for the multiple primary endpoint but not the co-primary.
This is intuitive given that the treatment effect observed in the SLEDAI outcome is smallest
and is largest for the PGA outcome. The effect on the power of removing an endpoint and
altering the correlation between endpoints is shown in the Appendix.
Table 2 shows the sample size required per group assuming that a future trial in SLE is to
be conducted using the composite responder endpoint, allowing for uncertainty in σ. The
estimated variance for the risk difference from the trial dataset is σδ = 0.048 with correlation
parameters ρ12 = 0.448, ρ13 = 0.521, ρ14 = 0.003, ρ23 = 0.448, ρ24 = −0.031, ρ34 = 0.066. For
a risk difference of 0.20, the required sample size per group is 20, compared to 100 for 88%
power in the standard binary method. Accounting for uncertainty in the latent variable
treatment effect variance, σδ = 0.10 would increase the required sample size per group to 40,
which is a more conservative estimate for use in practice. If the method were to be employed
for increased power, rather than a decrease in required sample size, the estimated power of
the latent variable method is over 99.99% for sample sizes giving 88% power at the 0.10 alpha
level in the binary method. The empirical power is shown for the latent variable method in
1000 simulated datasets, which is approximately 88% for each sample size, as required.
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Table 2: Sample sizes required using the latent variable method (nlat) and the binary method
(nbin) for overall power 1− β ≈ 88%, α = 0.10, k2 = 2, ko = K = 1 to detect a response risk
difference of 0.20, 0.18 and 0.16 as in the original MUSE trial. Estimated power is shown
from the latent variable method for the sample size required by the binary method
Risk difference σ nlat Empirical power (%) nbin Power (%)
0.20 0.05 20 88.05 100 99.99
0.20 0.06 24 87.01 100 99.99
0.20 0.07 28 87.62 100 99.98
0.20 0.08 32 87.04 100 99.96
0.20 0.09 36 87.83 100 99.89
0.20 0.10 40 88.12 100 99.89
5. Behaviour of Power Function and Sample Size for Composite Endpoints
We can further explore the properties of the functions proposed for composite endpoints
empirically and consider how factors such as the correlation structure and drivers of response
impact on the resulting power or sample size. As the primary purpose of using the latent
variable model in this context is for efficiency gain, we will compare the power and sample
size required using the technique we proposed with that required when the standard binary
analysis is conducted, using only the response indicator for each patient (McMenamin et al.,
2019).
5.1 One Continuous, One Ordinal, One Binary
The probability of response in each arm, the overall power and sample size per arm is
determined as illustrated in Section 3.3. We begin by considering the case where the com-
posite is a combination of one continuous, one ordinal and one binary outcome and the
components are dichotomised at their mean so that all three are responsible for discriminating
between responders and non-responders, i.e. all components drive response. We generate 1000
simulated datasets and fit the model to each, using the median variance estimate for σ2.
Figure 2 shows the change in estimated sample size per group as the overall treatment effect
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Figure 2: Estimated sample size per group for different values of the risk difference using the
latent variable and standard binary methods when the composite endpoint is formed from
one continuous, one ordinal and one binary outcome, where all components drive response
and correlations between the outcomes are between 0 and 0.8, where ρ = (ρ12, ρ13, ρ23)
on the composite endpoint changes and everything else remains constant. This is shown
for a range of correlations between the three endpoints. The sample size required for the
latent variable method generally decreases slightly as the correlation between the endpoints
increases, except when the correlation is already high.
Figure 3 shows boxplots of the estimated reduction in required sample size when employing
the latent variable rather than the standard binary method for a range of correlations between
the endpoints. This is shown for the scenarios where response is driven by (Y1, Y2, Y3), (Y1, Y3)
and (Y3). In the case where all three components drive response and the correlation between
the endpoints is zero, the latent variable method can reduce the sample size by 18-77%.
However when there is correlation between the endpoints, the sample size is reduced by
80-90%. A similar pattern occurs when response is driven by the continuous and binary
components, however there is a small drop in efficiency gains. For example, when the
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Figure 3: Boxplots of the estimated reduction in required sample size from employing the
latent variable method instead of the standard binary method for a range of correlations
between one continuous, one ordinal and one binary measure when all outcomes have equal
treatment effect. Response is driven by all components in the top panel, the continuous and
binary in the middle panel and only the binary in the bottom panel
correlation between endpoints is low, the reduction in required sample size drops from 85%
to approximately 77%, indicating that the ordinal component with 5 levels contributes to
the increased precision. When the binary component is the only driver of response and there
is no correlation between the endpoints, the median sample size required is the same for both
methods. However, when the binary component is the only driver of response and there is
correlation present between the endpoints, the latent variable method offers precision gains
over the standard binary method. The magnitude of the gain depends on the strength of the
correlation between the endpoints, where a higher correlation results in a larger reduction in
required sample size. Tables confirming that the empirical power of the method is close to
80% and the sample sizes required for different correlation, response drivers and treatment
effect structures for both methods are included in the Appendix.
5.2 Two Continuous, One Ordinal, One Binary
As well as considering a composite endpoint made up of one of each type of component,
it is interesting to consider the efficiency gains from modelling an additional continuous
component. In this instance Y1 and Y2 are continuous measures, Y3 is ordinal and Y4 is binary.
The results are included in the Appendix, which show that when using the latent variable
method, adding a second continuous component which also drives treatment response can
reduce the median required sample size by a further 46-58% for the different correlation
structures investigated. The estimated percentage reduction in required sample size from
using the latent variable method for these four components is also shown in the Appendix.
When the correlation between the components is zero, the median reduction in sample size
is 80%. For any correlation between the outcomes, the median reduction in required sample
size is approximately 94%. Furthermore, the results indicate that most of the efficiency gains
are obtained from the continuous measures and only a very small amount of this is from the
ordinal variable.
Figure 4 shows the sample sizes required across different treatment effect structures, for
different components driving response with varying correlation between the components.
The sample size required is the same across different treatment effect structures in the
components, including when the effects of components are in different directions, as in δ1 =
−δ2. The sample sizes required are similar when response is driven by (Y1, Y2, Y3, Y4) and
(Y1, Y2, Y3). In this setting the sample size is largest for zero correlation and reduces when
the components are correlated.
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Figure 4: Boxplots of the estimated sample size per group from 1000 simulated datasets
using the latent variable method for composites containing two continuous, one ordinal and
one binary component and correlation between endpoints is zero, low=0.3, medium=0.5
or high=0.8. These are shown when response is driven by (Y1, Y2, Y3, Y4), (Y1, Y2, Y3) or
(Y1, Y2, Y4) and the treatment effect structure in the components is δ1 = δ2 = δ3 = δ4,
δ3 = δ4 = 0 or δ1 = −δ2
6. Discussion
The work in this paper demonstrated the various ways in which a latent variable framework
may be employed for mixed continuous, ordinal and binary outcomes. We illustrated sample
size determination in the case of mixed continuous, ordinal and binary co-primary outcomes.
We extended this to allow for sample size determination in the case of mixed multiple primary
endpoints and proposed a technique to estimate the sample size when using a latent variable
model for the underlying structure of a mixed composite endpoint. Sample size determination
in all three cases requires the assumptions of the latent variable framework where discrete
variables are treated as continuous variables subject to estimable thresholds. This formulation
provides maximum likelihood estimates of latent means and correlation parameters which
can be used to characterise the joint distribution. For co-primary and multiple primary
endpoints the resulting hypothesis is based on an intersection or union of the hypotheses for
the individual outcomes and so is multivariate in nature. However, for composite responder
endpoints the hypothesis of interest is stated in relation to the overall responder endpoint and
so is univariate. Sample size estimation in this case can make use of the standard power and
sample size functions but requires the distribution of the test statistic under the alternative
hypothesis which we approximate using a Taylor series expansion.
We applied the methods to a numerical example based on a phase IIb study. For the
correlation structure observed in the MUSE trial, the sample size required for the co-primary
endpoints was similar to but greater than that required for the individual endpoint with the
lowest effect size. Alternatively, the sample size required for the multiple primary endpoint
changes based on the variance assumed for the outcome with the largest treatment effect,
however is lower than that required by the individual endpoint. The sample size required
for the composite endpoint was slightly larger than that required for the multiple primary
endpoint and similar to that required for the individual endpoint with the largest effect size.
Given that in the composite case we are concerned with the overall binary response endpoint,
we compared the sample sizes required for the endpoint using the latent variable model with
the standard binary method. These findings were in agreement with the power gains found
previously (McMenamin et al., 2019).
Due to the additional concerns for what drives the sample size requirement in the case of a
composite endpoint, we investigated the behaviour of the method under different scenarios
in a simulation study. We found that the sample size required depended only on the overall
treatment effect in the composite and not the treatment structure in the components. Sample
sizes varied depending on the components driving response and the correlation between
outcomes. We found that the magnitude of the increase in power offered by the latent variable
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method is smallest when the components are uncorrelated, however it is still substantial. One
important result from this work was quantifying the efficiency gain from adding a second
continuous component to the composite, provided both components drive response. We found
the median required sample size is reduced by 46-58% by including the additional continuous
component. The results showed that the inclusion of the ordinal component with five levels
is only responsible for a very small proportion of the precision gains. Given that the inclusion
of the ordinal component substantially increases complexity and computational demand, it
may be the case that it is sufficient to combine any ordinal components with the binary
outcome. It is likely that the precision gains will be larger for ordinal variables with a larger
number of categories however this will greatly increase computation time. Ordinal outcomes
with a large number of levels may be included as continuous components.
Our results show that the sample sizes required from the standard binary method increase
as the correlation between the components increase. These results are unexpected as sample
size typically decreases with increasing correlation. For the latent variable method the sample
size is largest for zero correlation, as we would expect. However, the sample size required is
smaller for low correlation between the components than for medium and high correlation
between outcomes. This ambiguity in how the correlation structure affects sample size is
problematic for practice. One possible conservative solution is to allow for uncertainty in the
correlations and use the maximum required sample size, which will still offer an improvement
over the binary method.
One practical consideration when calculating the sample size for a trial using the latent
variable model is the need to specify a large number of parameters, even in the case of only
a few outcomes. Additionally, in order to determine the sample size for composite endpoints
we use the delta method to obtain the variance of the risk difference, requiring the covariance
matrix of the parameter estimates. This can be obtained by fitting the model to pilot data
however this is potentially challenging and restrictive for a number of reasons. Firstly, it
requires that a pilot or earlier phase trial must have already taken place in order to apply
the method in a certain disease area. This is particularly undesirable in the case of rare
diseases which would benefit most from the increased efficiency but where trials are run very
infrequently. Furthermore, the pilot data could be fundamentally different to the future trial
and observed effects may be imprecise. Therefore, placing too much emphasis on the existing
data may lead to problems in the main trial. In theory, it is possible to specify the required
covariance parameters without data however this would be difficult in practice. Allowing for
uncertainty in the quantities and choosing conservative values should provide an appropriate
sample size estimate. An alternative when there is no data available is to apply the method
using the sample size required to achieve 80% power for the binary method and avail of the
study having a power much larger than 80%.
It is possible to extend this approach to use adaptive sample size re-estimation, or an
internal pilot to allow for reductions in the required sample size in the trial as we collect
more information about the treatment effect variability. Future work could also focus on
developing the method further to obtain an exact distribution for the test statistic rather
that the approximation obtained using the delta method.
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Appendix
Table 3: Empirical power (%) for n = nC = nT , α = 0.05, δ = µT − µC : overall risk
difference on the composite, δ1 = δ2 = δ3, for a combination of correlations ranging from 0,
L=0.3, M=0.5, H=0.8 using the latent variable method when the composite is made up of
one continuous, one ordinal and one binary outcome
Response δ n=50 n=100 n=200
000 MMM HHH 000 MMM HHH 000 MMM HHH
Y1, Y2, Y3 0.05 79.1 80.1 80.3 80.0 80.0 80.3 80.5 80.1 79.8
0.10 80.1 80.4 80.1 80.0 80.4 79.9 80.1 80.0 80.2
0.15 80.8 80.9 80.4 80.2 80.5 80.0 80.3 80.2 80.4
Y1, Y3 0.05 79.8 80.2 80.1 79.9 80.1 80.3 80.2 79.5 80.1
0.10 80.1 80.3 80.0 79.9 80.2 80.1 80.0 80.0 79.8
0.15 80.2 80.4 80.3 80.1 80.2 80.7 80.3 80.1 80.0
Y3 0.05 80.1 79.7 80.2 80.1 79.2 80.4 80.0 80.1 79.9
0.10 80.4 80.0 80.3 79.7 80.1 80.2 80.4 80.5 80.2
0.15 80.0 80.2 80.1 80.2 80.2 80.0 80.1 80.1 80.2
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Figure 5: Overall power 1 − β to detect the treatment effects assumed from the MUSE
trial for the systemic lupus erythematosus co-primary endpoints and individual endpoints
for different sample sizes per group n = nC = nT for co-primary endpoints PGA, BILAG
and Taper (left) and co-primary endpoints PGA and Taper (right)
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Figure 6: Overall power 1 − β to detect the treatment effects assumed from the MUSE
trial for the systemic lupus erythematosus co-primary endpoints for different sample sizes
per group n = nC = nT and differing correlations between outcomes, where Low=0.3,
Medium=0.5 and High=0.8
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Figure 7: Boxplots of the estimated reduction in required sample size in 1000 simulated
datasets from employing the latent variable method instead of the standard binary method
for correlations of zero, low=0.3, medium=0.5 and high=0.8 between two continuous (Y1, Y2),
one ordinal (Y3) and one binary (Y4) measure. Response is driven by all components in the
top panel, two continuous and ordinal in the middle panel and two continuous and binary
in the bottom panel
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Figure 8: Boxplots comparing the estimated sample size from 1000 simulated datasets
using the latent variable method for composites containing one continuous, one ordinal
and one binary component and composites containing two continuous, one ordinal and one
binary component, when all outcomes drive response. Correlations between components are
low=0.3, medium=0.5 and high=0.8, the risk difference between treatment arms in 0.2 and
the treatment effect is the same on all components.
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Table 4: Median sample sizes n = nC = nT for overall power 1 − β ≈ 80%, α = 0.05,
km = ko = K = 1, δ = µT − µC : overall risk difference on the composite, δ† : treatment
effect structure in the components, for a combination of correlations 0, L=0.3, M=0.5, H=0.8
using the latent variable model when the composite is made up of one continuous, one ordinal
and one binary outcome
Response δ† δ Correlation (ρ12, ρ13, ρ23)
000 00H LLL LLH MMM MMH HHH
Y1, Y2, Y3 δ1 = δ2 = δ3 0.05 206 339 128 119 112 108 145
0.10 52 85 32 30 28 27 38
0.15 23 38 15 14 13 12 17
δ3 = 0 0.05 201 334 123 117 105 112 159
0.10 51 84 31 30 27 28 40
0.15 23 38 14 13 12 13 18
δ2 = δ3 = 0 0.05 197 329 119 114 101 106 121
0.10 49 81 29 29 27 21 30
0.15 21 36 14 13 12 12 15
Y1, Y3 δ1 = δ2 = δ3 0.05 474 494 289 200 267 205 240
0.10 119 124 73 50 67 52 60
0.15 53 55 33 23 30 23 27
δ3 = 0 0.05 468 499 286 195 264 203 248
0.10 117 125 72 49 66 51 62
0.15 52 56 32 22 30 23 28
δ2 = δ3 = 0 0.05 470 501 287 196 264 204 249
0.10 119 123 73 49 67 51 63
0.15 53 55 32 23 31 24 28
Y3 δ1 = δ2 = δ3 0.05 1493 1472 1250 1113 948 793 609
0.10 374 368 313 279 237 199 153
0.15 166 164 139 124 106 89 68
δ3 = 0 0.05 1502 1468 1256 1113 960 806 622
0.10 376 367 315 279 240 202 156
0.15 176 164 140 124 107 90 70
δ2 = δ3 = 0 0.05 1504 1465 1259 1115 963 807 624
0.10 376 370 316 280 241 203 156
0.15 174 164 139 126 106 90 70
Table 5: Median sample sizes n = nC = nT for overall power 1 − β ≈ 80%, α = 0.05,
km = ko = K = 1, δ = µT − µC : overall risk difference on the composite, δ† : treatment
effect structure in the components, for a combination of correlations ranging from 0, L=0.3,
M=0.5, H=0.8 using the standard binary method when the composite is made up of one
continuous, one ordinal and one binary outcome
Response δ† δ Correlation (ρ12, ρ13, ρ23)
000 00H LLL LLH MMM MMH HHH
Y1, Y2, Y3 δ1 = δ2 = δ3 0.05 680 965 980 1141 1138 1214 1352
0.10 170 242 245 286 285 304 338
0.15 76 108 109 127 127 135 151
δ3 = 0 0.05 628 939 928 1098 1102 1183 1332
0.10 157 235 232 275 276 296 333
0.15 70 105 104 122 123 132 148
δ2 = δ3 = 0 0.05 609 920 914 1086 1097 1171 1310
0.10 147 231 228 270 271 290 328
0.15 68 101 101 119 121 130 146
Y1, Y3 δ1 = δ2 = δ3 0.05 1127 1136 1255 1261 1334 1320 1425
0.10 282 284 314 316 334 330 357
0.15 126 127 140 141 149 147 159
δ3 = 0 0.05 1078 1072 1216 1218 1298 1296 1403
0.10 270 268 304 305 325 324 351
0.15 120 120 136 136 145 144 156
δ2 = δ3 = 0 0.05 1066 1063 1202 1209 1296 1297 1403
0.10 263 259 300 299 319 324 351
0.15 121 119 133 131 143 143 156
Y3 δ1 = δ2 = δ3 0.05 1547 1548 1550 1548 1550 1550 1549
0.10 387 387 388 387 388 388 388
0.15 172 172 173 172 173 173 173
δ3 = 0 0.05 1544 1545 1549 1548 1549 1548 1545
0.10 386 387 388 387 388 387 387
0.15 172 172 173 172 173 172 172
δ2 = δ3 = 0 0.05 1544 1546 1549 1546 1551 1549 1545
0.10 386 389 387 385 388 388 387
0.15 173 172 173 173 172 172 172
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Table 6: Median sample sizes per group n = nC = nT for overall power 1 − β ≈ 80%,
α = 0.05, km = 2, ko = K = 1, δ = µT − µC : overall risk difference on the composite ,
δ†: treatment effect structure in the components, for a combination of correlations 0, L=0.3,
M=0.5, H=0.8 using the latent variable model when the composite is comprised of two
continuous, one ordinal and one binary outcome
Response δ† δ Correlation (ρ12, ρ13, ρ14, ρ23, ρ24, ρ34)
000000 LLLLLL MMMMMM HHHHHH
Y1, Y2, Y3, Y4 δ1 = δ2 = δ3 = δ4 0.05 70 51 41 81
0.10 18 13 11 21
0.15 8 6 5 9
δ3 = δ4 = 0 0.05 62 41 47 67
0.10 16 11 12 17
0.15 7 5 6 8
δ1 = −δ2 0.05 55 34 45 72
0.10 14 9 12 18
0.15 7 4 5 8
Y1, Y2, Y3 δ1 = δ2 = δ3 = δ4 0.05 139 71 63 105
0.10 35 18 16 27
0.15 16 8 7 12
δ3 = δ4 = 0 0.05 120 63 75 85
0.10 30 16 19 22
0.15 13 7 9 10
δ1 = −δ2 0.05 105 50 76 99
0.10 27 13 19 25
0.15 12 6 9 11
Y1, Y2, Y4 δ1 = δ2 = δ3 = δ4 0.05 166 106 105 112
0.10 42 27 27 28
0.15 19 12 12 13
δ3 = δ4 = 0 0.05 147 105 113 111
0.10 37 27 29 28
0.15 17 12 13 13
δ1 = −δ2 0.05 132 78 88 86
0.10 33 20 22 22
0.15 15 9 10 10
Table 7: Median sample sizes per group n = nC = nT for overall power 1 − β ≈ 80%,
α = 0.05, km = 2, ko = K = 1, δ = µT − µC : overall risk difference on the composite, δ†:
treatment effect structure in the components, for a combination of correlations 0, L=0.3,
M=0.5, H=0.8 using the standard binary method when the composite is comprised of two
continuous, one ordinal and one binary outcome
Response δ† δ Correlation (ρ12, ρ13, ρ14, ρ23, ρ24, ρ34)
000000 LLLLLL MMMMMM HHHHHH
Y1, Y2, Y3, Y4 δ1 = δ2 = δ3 = δ4 0.05 386 739 665 1240
0.10 97 185 167 310
0.15 43 83 74 138
δ3 = δ4 = 0 0.05 324 665 867 1205
0.10 81 167 217 302
0.15 36 74 97 134
δ1 = −δ2 0.05 331 666 858 1169
0.10 83 167 215 293
0.15 37 74 96 130
Y1, Y2, Y3 δ1 = δ2 = δ3 = δ4 0.05 690 956 912 1300
0.10 173 239 228 325
0.15 77 107 102 145
δ3 = δ4 = 0 0.05 650 912 1053 1283
0.10 163 228 264 321
0.15 73 102 117 143
δ1 = −δ2 0.05 605 866 1017 1232
0.10 152 217 255 308
0.15 68 97 113 137
Y1, Y2, Y4 δ1 = δ2 = δ3 = δ4 0.05 690 962 919 1298
0.10 173 241 230 325
0.15 77 107 103 145
δ3 = δ4 = 0 0.05 642 919 1058 1281
0.10 161 230 265 321
0.15 72 103 118 143
δ1 = −δ2 0.05 610 876 1007 1225
0.10 153 219 252 307
0.15 68 98 112 137
